Abattis Bioceuticals Corp.
ATTBF
$0.00
$0.000.00%
| 09/30/2019 | 06/30/2019 | 03/31/2019 | 12/31/2018 | 09/30/2018 | |
|---|---|---|---|---|---|
| Revenue | 268.90K | 99.50K | 4.20K | 7.10K | 6.60K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 268.90K | 99.50K | 4.20K | 7.10K | 6.60K |
| Cost of Revenue | 87.00K | 38.40K | 0.00 | 1.50K | 1.50K |
| Gross Profit | 182.00K | 61.10K | 4.20K | 5.60K | 5.10K |
| SG&A Expenses | 3.05M | -2.28M | 977.20K | 8.83M | 12.49M |
| Depreciation & Amortization | 82.20K | -1.41M | 63.80K | 56.40K | 47.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.22M | -3.65M | 1.04M | 8.89M | 12.56M |
| Operating Income | -2.95M | 3.75M | -1.04M | -8.88M | -12.55M |
| Income Before Tax | -2.31M | -42.80M | -47.63M | -56.74M | -59.90M |
| Income Tax Expenses | -100.00 | 3.80K | -- | -- | -- |
| Earnings from Continuing Operations | -2.31 | -42.80 | -47.63 | -56.74 | -59.90 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 14.40K | -277.10K | -277.10K | -277.10K | -277.10K |
| Net Income | -2.29M | -43.08M | -47.91M | -57.02M | -60.17M |
| EBIT | -2.95M | 3.75M | -1.04M | -8.88M | -12.55M |
| EBITDA | -2.89M | 3.80M | 485.30K | -7.36M | -11.04M |
| EPS Basic | 0.00 | -0.10 | -0.11 | -0.15 | -0.17 |
| Normalized Basic EPS | 0.00 | -0.03 | -0.04 | -0.06 | -0.07 |
| EPS Diluted | 0.00 | -0.10 | -0.11 | -0.15 | -0.17 |
| Normalized Diluted EPS | 0.00 | -0.03 | -0.04 | -0.06 | -0.07 |
| Average Basic Shares Outstanding | 1.88B | 1.83B | 1.73B | 1.56B | 1.29B |
| Average Diluted Shares Outstanding | 1.88B | 1.83B | 1.73B | 1.56B | 1.29B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
